Abstract:In our continuing search for novel natural products with antiplasmodial activity, an extract of Aniba citrifolia was found to have good activity, with an IC50 value less than 1.25 μg/mL. After bioassay-directed fractionation, the known indolizinium alkaloid anibamine (1) and the new indolizinium alkaloid anibamine B (2) were isolated as the major bioactive constituents, with antiplasmodial IC50 values of 0.170 and 0.244 μM against the drug-resistant Dd2 strain of Plasmodium falciparum. The new coumarin anibomarin A (3), the new norneolignan anibignan A (5), and six known neolignans (7-12) were also obtained. The structures of all the isolated compounds were determined based on analyses of 1D and 2D NMR spectroscopic and mass spectrometric data, and the absolute configuration of anibignan A (5) was assigned from its ECD spectrum. Evaluation of a library of 28 anibamine analogues (13-40) indicated that quaternary charged analogues had IC50 values as low as 58 nM, while uncharged analogues were inactive or significantly less active. Assessment of the potential effects of anibamine and its analogues on the intraerythrocytic stages and morphological development of P. falciparum revealed substantial activity against ring stages for compounds with two C-10 side chains, while those with only one C-10 side chain exhibited substantial activity against trophozoite stages, suggesting different mechanisms of action.

The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents.

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

The Natural Product CCR5 Antagonist Anibamine and Its Analogs As Anti-Prostate Cancer Agents

Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents

ChemInform Abstract: Anibamine, a Natural Product CCR5 Antagonist, As a Novel Lead for the Development of Antiprostate Cancer Agents.

Regio- and Stereoselective Syntheses of the Natural Product CCR5 Antagonist Anibamine and Its Three Olefin Isomers.

Natural Product-Based Design, Synthesis and Biological Evaluation of Albiziabioside A Derivatives That Selectively Induce HCT116 Cell Death.

Design, Syntheses, and Characterization of Piperazine Based Chemokine Receptor CCR5 Antagonists As Anti Prostate Cancer Agents.

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Anibamine and Its Analogues: Potent Antiplasmodial Agents from Aniba Citrifolia.

Design, Syntheses and Biological Evaluation of Natural Product Aiphanol Derivatives and Analogues: Discovery of Potent Anticancer Agents

Spirolactone-type and Enmein-Type Derivatives As Potential Anti-Cancer Agents Derived from Oridonin

Design, synthesis, and antitumor activity of novel oleanolic acid analogues targeting EGFR

Cytotoxic Activity of Novel GnRH Analogs Conjugated with Mitoxantrone in Ovarian Cancer Cells

Synthesis, Biological Evaluation, and Molecular Docking Studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline Derivatives As Novel Anticancer Agents

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Design, Synthesis and Anti-Ovarian Cancer Activities of Thieno[2,3-D] Pyrimidine Based Chimeric BRD4 Inhibitor/nitric Oxide-Donator

Design, Biological Characterization, and Discovery of Novel Cyclohexenyl Derivatives as Kinesin KIF18A Inhibitors for the Treatment of Ovarian Cancer

1,3,4-Oxadiazole Derivatives As Potential Antitumor Agents: Discovery, Optimization and Biological Activity Valuation

Synthesis, Biological Evaluation and Docking Studies of (E)-3-Aryl-2-(3,4,5-trimethoxybenzoyl) Acrylonitrile Derivatives as Anticancer Agents

Synthesis, Biological Evaluation, and Molecular Docking Studies of 1,3,4-Thiadiazol-2-amide Derivatives As Novel Anticancer Agents